Kulpreet Barn, MD
Advanced Heart Failure and Transplant Cardiology · Barnegat, NJNPI 1699064600
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 62.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2024 at $28,405 and has fallen 85.0% since, to $4,257 in 2025. Among advanced heart failure and transplant cardiology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $333.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$57K
- AstraZeneca$16K
- Pfizer$15K
- Abiomed$614
- Biotronik Inc.$575
- Alnylam Pharmaceuticals Inc.$393
- plus $2K from 22 others
Across 32 payments — averaging $1706.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$55K
What the payments were for
- Consulting fees$46,81151%
- Speaking & faculty fees$31,10934%
- Travel & lodging$3,8734%
- Food & beverage$9,77111%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 131 | $56,915 |
| AstraZeneca | 19 | $16,295 |
| Pfizer | 19 | $14,824 |
| Abiomed | 5 | $614 |
| Biotronik Inc. | 13 | $575 |
| Alnylam Pharmaceuticals Inc. | 16 | $393 |
| Actelion Pharmaceuticals US, Inc. | 18 | $374 |
| Edwards Lifesciences | 2 | $240 |
| Boston Scientific | 4 | $202 |
| Bridgebio Pharma, Inc. | 6 | $198 |
| Cvrx, Inc. | 3 | $198 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $102 |
| Merck | 6 | $94 |
| Cardiac Dimensions, Inc. | 2 | $77 |
| Impulse Dynamics (USA) Inc. | 3 | $72 |
| La Jolla Pharmaceutical Company | 1 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Eurofins Viracor, LLC | 1 | $58 |
| Novartis | 2 | $36 |
| Boehringer Ingelheim | 2 | $35 |
| Bayer | 2 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $30 |
| One Lambda, Inc. | 2 | $26 |
| Endotronix, Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$30,711
- VYNDAQEL$14,503
- FARXIGA$12,714
- HeartMate 3 Left Ventricular Assist Device$12,428
- MitraClip$5,566
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$2,074
- HeartMate Touch$1,580
- CardioMEMS HF System$1,330
- HeartMate 3 Left Ventricular Dev$637
- CARDIOMEMS$450
- Impella$447
- Barostim Neo System$160
- SAPIEN 3 Ultra RESILIA$143
- AMVUTTRA$142
- GENERAL - THERAPIES$132
- Attruby$127
- HeartMate$115
How this compares
$91,606 in reported general payments places this provider in the 90th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
See all advanced heart failure and transplant cardiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $264,528 |
| OpsumitMacitentan | 11 | $139,288 |
| Warfarin Sodium | 218 | $2,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax | $14,824 | $264,52812 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $374 | $139,28811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
Other advanced heart failure and transplant cardiology in Barnegat
- Abhishek SinghMorristown$283K
- Kanika ModyHackensack$107K
- Robert MohapatraSewell$84K
- Saad AhmadMorristown$74K
- Mark ZuckerMorristown$44K
- Saurabh KapoorEnglewood$27K
- Ketan GalaCherry Hill$18K
- Raul FloresMorristown$11K
- Ahmed SeliemCamden$8K
- Eman RashedNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.